1.Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study
Young Ji LEE ; Ga Won LEE ; Wan Seok SEO ; Bon Hoon KOO ; Hye Geum KIM ; Eun Jin CHEON
Journal of Korean Medical Science 2019;34(42):e287-
BACKGROUND: We evaluated the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD). METHODS: We included 24 adult patients with TRD and 12 healthy adults. 24 TRD patients were assigned to the neurofeedback augmentation group (n = 12) and the medication-only (treatment as usual [TAU]) group (n = 12). The neurofeedback augmentation group underwent combined therapy comprising medication and 12–24 sessions of neurofeedback training for 12 weeks. To assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, pre- and post-treatment blood samples were obtained. Patients were evaluated using the Hamilton Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and at the 1-, 4-, and 12-week. RESULTS: From baseline to week 12, neurofeedback training reduced mean scores on HAM-D, BDI-II, CGI-S, and SDS, and increased mean EQ-5D-5L tariff score. In the neurofeedback augmentation group, the response and remission rates were 58.3% and 50.0%, respectively, at week 12. Changes in HAM-D, EQ-5D-5L tariff score, and SDS were significantly larger in the neurofeedback group than in the medication-only (TAU) group. No significant difference in BDNF level was found pre- vs. post-treatment in any of the groups. CONCLUSION: Despite the small sample size, these results suggest that neurofeedback treatment may be effective as an augmentation treatment, not only for depressive symptoms, but also for functional recovery, in patients with TRD. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004183 ClinicalTrials.gov Identifier: NCT04078438
Adult
;
Brain-Derived Neurotrophic Factor
;
Classification
;
Depression
;
Depressive Disorder, Major
;
Humans
;
Information Services
;
Neurofeedback
;
Pilot Projects
;
Quality of Life
;
Sample Size
2.Acute Recurrent Pericarditis Accompanied by Graves' Disease.
Eun Hee KOO ; Sung Min KIM ; Sun Mi PARK ; Ji Won PARK ; Eun Kyoung KIM ; Ga Yeon LEE ; Sung A CHANG ; Sang Chol LEE ; Yeon Hyeon CHOE
Korean Circulation Journal 2012;42(6):419-422
The etiology of acute pericarditis is often thought to be autoimmune, and Graves' disease has been reported in a few series to manifest as acute pericarditis. Since the etiology of recurrent pericarditis is known to be more associated with autoimmune causes, recurrent acute pericarditis may be a potential cardiovascular complication of Graves' disease. We report a case of recurrent acute pericarditis that was presumed to be associated with Graves' disease which was controlled after management of the problem of the thyroid.
Graves Disease
;
Pericarditis
;
Thyroid Gland
3.A Comparison of AmBisome(R) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants.
Ga Won JEON ; Soo Hyun KOO ; Jang Hoon LEE ; Jong Hee HWANG ; Sung Shin KIM ; Eun Kyung LEE ; Wook CHANG ; Yun Sil CHANG ; Won Soon PARK
Yonsei Medical Journal 2007;48(4):619-626
PURPOSE: Amphotericin B is considered the treatment of choice for systemic candidiasis, but adverse effects may limit its use. An alternative option for the treatment of candidiasis includes lipid preparations of amphotericin B. This study investigated the safety and efficacy of AmBisome(R), a lipid formulation of amphotericin B containing liposomal structures, for the treatment of systemic candidiasis in very low birth weight infants (VLBWI). MATERIALS AMD METHODS: Data from 26 VLBWI treated with AmBisome(R) in the study group (AmBisome group) from October 2003 to July 2006 were compared with data from 20 VLBWI treated with amphotericin B as a historical control (Amphotericin group). This study was a prospective, historical control, multi-center trial. RESULTS: Candida spp. was isolated in 73% (19/26) of the cases for the AmBisome group and 90% (18/20) of the cases for the Amphotericin group. The fungal eradication rate and the time to eradication was 84% (16/19) and 9+/-8 days in the AmBisome group, and 89% (16/18) and 10+/-9 days in the Amphotericin group, respectively (p=0.680 vs p=0.712). The major adverse effects were lower in the AmBisome group (renal toxicity, 21% vs 55%, p=0.029; hepatotoxity, 25% vs 65%, p=0.014, AmBisome group vs Amphotericin group, respectively). There was no significant difference in mortality attributed to systemic candidiasis (12% in the AmBisome group, 10% in the Amphotericin group, p=0.868). CONCLUSION: AmBisome(R) is effective and safe for treating systemic fungal infections in VLBWI.
Amphotericin B/adverse effects/*therapeutic use
;
Candidiasis/*drug therapy
;
Female
;
Humans
;
Infant, Newborn
;
*Infant, Very Low Birth Weight
;
Male
4.Evaluation of Perinatal and Management Factors Associated with Improved Survival in Extremely Low Birth Weight Infants.
Sung Eun PARK ; Ga Won JEON ; Chang Won CHOI ; Jong Hee HWANG ; Soo Hyun KOO ; Yu Jin KIM ; Chang Hoon LEE ; Yun Sil CHANG ; Won Soon PARK
Korean Journal of Pediatrics 2005;48(12):1324-1329
PURPOSE: The aim of this study was to evaluate recent improvements in the survival rate of extremely low birth weight (ELBW) infants and to identify perinatal and management factors that are associated with improved survival. METHODS: Two groups of ELBW infants who were admitted to our neonatal intensive care unit (NICU) during two distinct eras: November 1994-December 1999 (Period 1: n=100) and January 2000-April 2004 (Period 2: n=166) were retrospectively reviewed. RESULTS: Despite the younger gestational age and smaller birth weight of the ELBW infants in period 2, not only did their survival rate increased to 75 percent from 60 percent in period 1, but their incidence of morbidities such as bronchopulmonary dysplasia, confimed sepsis and intraventricular hemorrhage (> or =Grade III) also declined. Factors significantly associated with improved survival included the use of antenatal steroids, a longer duration of nasal continuous positive airway pressure and the absence of intraventricular hemorrhage (> or =Grade III). CONCLUSION: We believe that optimized clinical practice, that emphasized less invasive care, contributed to the recent improvements in the survival rate of ELBW infants.
Infant
;
Male
;
Female
;
Infant, Newborn
;
Humans
;
Incidence
5.A Rare Case of Hyponatremia Caused by Reset Osmostat in a Neonate with Cleft Lip, Cleft Palate, and Imperforate Anus.
Jung Gu AHN ; Jeong Eun LEE ; Woo Yeong CHUNG ; Soo Hyun KOO ; Jaeho SHIN ; Ga Won JEON
Neonatal Medicine 2018;25(3):131-135
Hyponatremia is defined as a plasma sodium concentration of < 135 mEq/L. It is a common electrolyte imbalance in newborns. We report the case of a term neonate with cleft lip, cleft palate, imperforate anus, normal male karyotype, and chronic hyponatremia. On the 4th day of life, he showed hyponatremia (plasma sodium concentration 130 mEq/L) with low serum osmolality (275 mOsm/kg), high urine sodium (116.7 mEq/L), and high urine osmolality (412 mOsm/kg). His thyroid and adrenal functions were normal. Despite intravenous and oral sodium supplementation and hydrocortisone treatment, hyponatremia persisted. Brain magnetic resonance imaging showed normal results. He was diagnosed as having reset osmostat, a rare subtype of the syndrome of inappropriate secretion of antidiuretic hormone characterized by a subnormal threshold for antidiuretic hormone secretion, with hypotonic hyponatremia.
Anus, Imperforate*
;
Brain
;
Cleft Lip*
;
Cleft Palate*
;
Humans
;
Hydrocortisone
;
Hyponatremia*
;
Inappropriate ADH Syndrome
;
Infant, Newborn*
;
Karyotype
;
Magnetic Resonance Imaging
;
Male
;
Osmolar Concentration
;
Plasma
;
Sodium
;
Thyroid Gland
6.Hyperammonemic Encephalopathy Caused by the c.386+5G>A Mutation in OTC Gene in a Young Adult Woman
Yi-Seul CHOO ; Ga eun KOO ; Yu-Jin KANG ; Dongwook KANG ; Young Jun KO ; Ji Young PARK ; Chan-Young PARK ; Su-Hyun HAN
Journal of the Korean Neurological Association 2024;42(1):62-65
Noncirrhotic hyperammonemia as a cause of acute confusion remains diagnostic challenge. Deficiency of ornithine transcarbamylase (OTC) is the urea cycle disorder, inborn errors caused by a defect of the enzymes in the urea cycle, leading to an accumulation of ammonia mainly in newborn. There were very few cases, in which OTC deficiency result in hyperammonemia in adulthood. Herein, we report a young adult woman of hyperammonemic encephalopathy with OTC deficiency, diagnosed by high blood ammonia, glutamine and low plasma levels of citrulline. Next generation sequencing showed the c.386+5G>A mutation of the OTC gene.
7.Preserved Hippocampal Glucose Metabolism on 18F-FDG PET after Transplantation of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells in Chronic Epileptic Rats.
Ga Young PARK ; Eun Mi LEE ; Min Soo SEO ; Yoo Jin SEO ; Jungsu S OH ; Woo Chan SON ; Ki Soo KIM ; Jae Seung KIM ; Joong Koo KANG ; Kyung Sun KANG
Journal of Korean Medical Science 2015;30(9):1232-1240
Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) may be a promising modality for treating medial temporal lobe epilepsy. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a noninvasive method for monitoring in vivo glucose metabolism. We evaluated the efficacy of hUCB-MSCs transplantation in chronic epileptic rats using FDG-PET. Rats with recurrent seizures were randomly assigned into three groups: the stem cell treatment (SCT) group received hUCB-MSCs transplantation into the right hippocampus, the sham control (ShC) group received same procedure with saline, and the positive control (PC) group consisted of treatment-negative epileptic rats. Normal rats received hUCB-MSCs transplantation acted as the negative control (NC). FDG-PET was performed at pre-treatment baseline and 1- and 8-week posttreatment. Hippocampal volume was evaluated and histological examination was done. In the SCT group, bilateral hippocampi at 8-week after transplantation showed significantly higher glucose metabolism (0.990 +/- 0.032) than the ShC (0.873 +/- 0.087; P < 0.001) and PC groups (0.858 +/- 0.093; P < 0.001). Histological examination resulted that the transplanted hUCB-MSCs survived in the ipsilateral hippocampus and migrated to the contralateral hippocampus but did not differentiate. In spite of successful engraftment, seizure frequency among the groups was not significantly different. Transplanted hUCB-MSCs can engraft and migrate, thereby partially restoring bilateral hippocampal glucose metabolism. The results suggest encouraging effect of hUCB-MSCs on restoring epileptic networks.
Animals
;
Chronic Disease
;
Cord Blood Stem Cell Transplantation/*methods
;
Epilepsy, Temporal Lobe/*metabolism/pathology/*therapy
;
Fluorodeoxyglucose F18/*pharmacokinetics
;
Hippocampus/*metabolism/*pathology/surgery
;
Male
;
Mesenchymal Stem Cell Transplantation/methods
;
Radiopharmaceuticals/pharmacokinetics
;
Rats
;
Rats, Sprague-Dawley
;
Reproducibility of Results
;
Sensitivity and Specificity
;
Tissue Distribution
;
Treatment Outcome
8.Multicenter Study on the Clinician's Diagnostic and Therapeutic Approaches for Benign Paroxysmal Positional Vertigo in Korea
Eun Ju JEON ; Won Ho CHUNG ; Jeong Hwan CHOI ; Eui Cheol NAM ; Hong Ju PARK ; Jong Dae LEE ; Won Sang LEE ; Kyu Sung KIM ; Eui Kyung GOH ; Ja Won KOO ; Min Bum KIM ; Min Beom KIM ; Se Hyung KIM ; Young Jin KIM ; Chang Hee KIM ; Sung Il NAM ; Seog Kyun MUN ; Ga Young PARK ; Sang Yoo PARK ; Shi Nae PARK ; Chang Hoon BAE ; Sung Hyun BOO ; Myung Whan SUH ; Jae Hyun SEO ; Eun Jin SON ; Jae Jun SONG ; Jae Jin SONG ; Joong Wook SHIN ; Dae Bo SHIM ; Seong Ki AHN ; Hye Youn YOUM ; Shin Young YOO ; Dong Hee LEE ; Seung Hwan LEE ; Chang Ho LEE ; Hyun Seok LEE ; Hwan Ho LEE ; Hyo Jeong LEE ; Yun Hoon CHOUNG ; Seung Hyo CHOI ; Jee Sun CHOI ; Seok Min HONG ; Sung Kwang HONG
Journal of the Korean Balance Society 2013;12(3):79-92
BACKGROUND AND OBJECTIVES: It is necessary to establish the most efficient diagnostic and therapeutic method for benign paroxysmal positional vertigo (BPPV), which is appropriate for Korean healthcare system. We aimed to evaluate current state of Korean clinician's diagnostic and therapeutic approaches for BPPV. MATERIALS AND METHODS: A 16-item survey was emailed to the members of dizziness department of Otology Research Interest Group in the Korean Otologic Society (n=68). 43 were returned and analyzed. RESULTS: All respondents (100%) used Dix-Hallpike test as a diagnostic tool for vertical canal-BPPV. Supine roll test was used for diagnosing lateral canal BPPV in nearly all the respondents (97.7%). Epley maneuver was chosen as otolith repositioning maneuver (ORM) for posterior canal BPPV in all respondents and barbecue rotation (BBQ) was used for treating lateral canal BPPV with geotropic nystagmus in 95.3% of respondents. Extreme variation was noted for therapeutic approach of lateral canal BPPV with ageotropic nystagmus BBQ, with 4 kinds of ORM and adjunctive measures to liberate otolith from cupula, while BBQ was again the most commonly used ORM (76.7%). CONCLUSION: The development of practical and efficient ORM for lateral canal BPPV with ageotropic nystagmus is necessary.
Surveys and Questionnaires
;
Delivery of Health Care
;
Dizziness
;
Electronic Mail
;
Korea
;
Otolaryngology
;
Otolithic Membrane
;
Public Opinion
;
Vertigo